Clinical Trials Directory

Trials / Completed

CompletedNCT00733720

Buprenorphine Naltrexone-P1 A-Cocaine

Attenuation of Opioid Effects of Three Different Doses of Sublingual Buprenorphine / Naloxone by Oral Naltrexone in Healthy Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
8 (estimated)
Sponsor
National Institute on Drug Abuse (NIDA) · NIH
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to determine if the opioid agonist effects of doses of 4/1 mg, 8/2 mg, and 16/4 mg of buprenorphine/naloxone can be completely blocked by 50 mg of oral naltrexone. This study will provide data to support the design of a similar study of the depot formulation of naltrexone and ultimately to study this combination for the treatment of cocaine dependence.

Conditions

Interventions

TypeNameDescription
DRUGSuboxone4/1mg, 8/2mg 16/4mg

Timeline

Start date
2008-08-01
Primary completion
2008-12-01
Completion
2009-01-01
First posted
2008-08-13
Last updated
2017-01-12

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00733720. Inclusion in this directory is not an endorsement.